DrugDashboards

Bleomycin

Bleomycin · BLEOMYCIN SULFATE 15 [USP'U]/1 · Injection, Powder, Lyophilized, For Solution · Intramuscular; Intrapleural; Intravenous; Subcutaneous · Hospira, Inc.

NDC 61703-0332-18 · 1 VIAL, SINGLE-DOSE in 1 CARTON / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE · ANDA · View full market →

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately. The price is down 17% over the past year, to $26.45 per unit. Put together: worth watching — several of the pressures that precede supply trouble are present at once. Historically, drugs in this position went on to a new shortage within 90 days about 0.4% of the time — roughly 3× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$26.45per EAinvoice-surveyed acquisition cost · Apr 22, 2026
  • Medicare Part B pays (ASP+6%)$24.84per billing unit (15 UNITS)HCPCS J9040 · Jul 1, 2026

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$20.00$40.00Dec 2024Sep 2026$26.45
9 price points · per EA · held since Invalid DateSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$50.46
Reported to Texas DSHS · 2026 annual filing · Pfizer Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 15 UNITS
$24.838
HCPCS J9040 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$931
35 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

30● Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

  • 2 active manufacturers+20
  • sterile injectable+10

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.4%chance of a new FDA shortage posting for bleomycin (injectable) in the next 90 days

sterile injectable · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 3× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA065031
TE code
AP
Approval date
Mar 10, 2000
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class I · OngoingDec 21, 2023
    PFIZER — Presence of particulate matter: glass

Manufacturers of Bleomycin (Injection, Powder, Lyophilized, For Solution)

LabelerStrengthFirst seenLast seen
Hospira, Inc.BLEOMYCIN SULFATE 15 [USP'U]/1Jul 15, 2026Sep 3, 2026
Hikma Pharmaceuticals USA Inc.BLEOMYCIN SULFATE 15 [USP'U]/1Jul 15, 2026Sep 2, 2026
Hikma Pharmaceuticals USA Inc.BLEOMYCIN SULFATE 30 [USP'U]/1Jul 15, 2026Sep 2, 2026
Hospira, Inc.BLEOMYCIN SULFATE 30 [USP'U]/1Jul 15, 2026Aug 31, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Bleomycin — NDC 61703-0332-18," retrieved September 3, 2026, https://drugdashboards.com/drug/61703033218.

Free to cite with attribution — see how the data is put together.